Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

$8.28 -0.03 (-0.36%)

Closing price 03/25/2025 04:00 PM Eastern

Extended Trading

$8.18 -0.09 (-1.15%)

As of 03/25/2025 07:10 PM Eastern

Day One Biopharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Day One Biopharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 7 have given a buy rating, and 1 has given a strong buy rating for DAWN.

Consensus Price Target

$32.29
289.92% Upside

According to the 8 analysts' twelve-month price targets for Day One Biopharmaceuticals, the average price target is $32.29. The highest price target for DAWN is $40.00, while the lowest price target for DAWN is $25.00. The average price target represents a forecasted upside of 289.92% from the current price of $8.28.

Get the Latest News and Ratings for DAWN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors.

DAWN Analyst Ratings Over Time

Type	Current Forecast 3/26/24 to 3/26/25	1 Month Ago 2/25/24 to 2/24/25	3 Months Ago 12/27/23 to 12/26/24	1 Year Ago 3/27/23 to 3/26/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$32.29	$35.71	$35.71	$40.60
Forecasted Upside	289.92% Upside	193.22% Upside	176.85% Upside	161.60% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Remove Ads

DAWN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DAWN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Day One Biopharmaceuticals Stock vs. The Competition

Type	Day One Biopharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.13	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	289.92% Upside	29,987.79% Upside	17.45% Upside
News Sentiment Rating	Positive News See Recent DAWN News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/25/2025	The Goldman Sachs Group 3 of 5 stars	Andrea Tan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$39.00 ➝ $27.00	+235.40%
3/5/2025	JPMorgan Chase & Co. 3 of 5 stars	Anupam Rama Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$39.00 ➝ $34.00	+264.81%
2/26/2025	Wedbush 4 of 5 stars	Robert Driscoll Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $32.00	+212.16%
2/26/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00	+170.73%
2/26/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andres Maldonado Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$40.00 ➝ $36.00	+204.57%
1/7/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$28.00 ➝ $25.00	+100.48%
11/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Bancroft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$40.00 ➝ $40.00	+183.69%
2/27/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:57 AM ET.

DAWN Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Day One Biopharmaceuticals is $32.29, with a high forecast of $40.00 and a low forecast of $25.00.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DAWN shares.
: According to analysts, Day One Biopharmaceuticals's stock has a predicted upside of 289.92% based on their 12-month stock forecasts.
: Day One Biopharmaceuticals has been rated by research analysts at Bank of America, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, The Goldman Sachs Group, and Wedbush in the past 90 days.
: Analysts like Day One Biopharmaceuticals more than other "medical" companies. The consensus rating for Day One Biopharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DAWN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:DAWN) was last updated on 3/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target